Detection of Serum Biochemical Markers in Elderly Patients with Type 2 Diabetes Mellitus and Its Relationship with Coronary Heart Disease

IRCMJ logo
PDF
HTML

Keywords

Apolipop protein A
Coronary heart disease
Glycated albumin
Homocysteine
Type 2 diabetes mellitus

How to Cite

ZhangJ., ShaoK., YangS., & MaQ. (2020). Detection of Serum Biochemical Markers in Elderly Patients with Type 2 Diabetes Mellitus and Its Relationship with Coronary Heart Disease. Iranian Red Crescent Medical Journal, 22(8). https://doi.org/10.32592/ircmj.2020.22.8.44

Abstract

Background: Coronary heart disease (CHD) is myocardial ischemia caused by coronary atherosclerosis and stenosis.

Objectives: This study aimed to investigate the relationship of CHD with glycated albumin (GA), glycosylated hemoglobin (HbA 1c), glucose (Glu), homocysteine (Hcy), triglyceride (TG), and apolipop protein A (apoA) levels in elderly patients with type 2 diabetes mellitus (T2DM). Moreover, it was attempted to predict which changes had a significant correlation with the occurrence of CHD in these biochemical indicators.

Methods: This clinical cohort study included a total of 472 patients admitted to our hospital from June 2018 to June 2019. They were then divided into three groups of concurrent (n=168, T2DM complicated with CHD), DM (n=148, T2DM alone), and control (n=156, healthy individuals).

Results: There were significant differences between the disease group (i.e., DM and concurrent groups) and control group in terms of GA (P=0.013, 28.58±8.01 vs. 15.77±1.44), HbA 1c (P=0.022, 9.5±1.5 vs. 5.5±0.5), Glu (P=0.012, 8.54±2.23 vs. 4.12±0.39), Hcy (P=0.031, 11.16±3.28 vs. 5.03±2.87), TG (P=0.021, 1.83±0.49 vs. 0.84±0.18), and apoA (P=0.031, 1.10±0.12 vs. 1.30±0.18).

Moreover, GA (P=0.025, 27.14±6.34 vs. 28.58±8.01; concurrent group vs. DM group), HbA 1c (P=0.033, 8.3±1.2 vs. 9.5±1.5; concurrent group vs. DM group), Glu (P=0.019, 8.62±3.56 vs. 8.54±2.23; concurrent group vs. DM group), Hcy (P=0.031, 17.56±6.36 vs. 11.16±3.28; concurrent group vs. DM group), total cholesterol ([TC); P=0.022, 3.06±0.20 vs. 3.69±0.29; concurrent group vs. DM group), and low-density lipoprotein ([LDL); P=0.037, 2.57±1.02 vs. 3.40±1.17; concurrent group vs. DM group) in disease group (DM group and concurrent group) were higher than those in the control group; however, apoA (P=0.023, 0.95±0.12 vs. 1.10±0.12; concurrent group vs. DM group) in disease group was lower than that in the control group. Furthermore, there were significant differences between the disease and control groups in terms of GA, HbA 1c, Glu, Hcy, TC, LDL, and apoA (P<0.05). Pearson correlation analysis between DM and concurrent groups was performed on the clinical parameters with statistical differences, and GA was highly correlated with HbA 1c and Glu (P<0.01).

Conclusion: High-risk patient screening with high levels of GA, Hcy, and apoA in elderly patients with T2DM can not only improve the symptoms of patients with targeted treatment but also reduce the incidence of CHD by timely intervention, which is of great significance to improve the quality of life of patients.

https://doi.org/10.32592/ircmj.2020.22.8.44
PDF
HTML

References

Giannopoulos S, Texakalidis P, Charisis N, Jonnalagadda AK, Chaitidis N, Giannopoulos S, et al. Synchronous carotid endarterectomy and coronary artery bypass graft (CABG) versus staged carotid artery stenting and CABG for patients with concomitant severe coronary and carotid stenosis: a systematic review and meta-analysis. Ann Vasc Surg. 2020;62:463-73. doi: 10.1016/j.avsg.2019.06.018. [PubMed: 31449948].

Harky A, Noshirwani A, Karadakhy O, Ang J. Comprehensive literature review of anomalies of the coronary arteries. J Card Surg. 2019;34(11):1328-43. doi: 10.1111/jocs.14228. [PubMed: 31449703].

Logan N, Islam MS, Chughtai JZ, Murphy NF. An atypical cause of myocardial infarction: case report of an obstructing papillary fibroelastoma of the aortic valve. Eur Heart J Case Rep. 2019;3(2):ytz058. doi: 10.1093/ehjcr/ytz058. [PubMed: 31449619].

Mortada I. Hyperuricemia, type 2 diabetes mellitus, and hypertension: an emerging association. Curr Hypertens Rep. 2017;19(9):69. doi: 10.1007/s11906-017-0770-x. [PubMed: 28770533].

Gao Y, Peterson E, Pagidipati N. Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease. Clin Cardiol. 2019;42(11):1063-70. doi: 10.1002/clc.23252. [PubMed: 31448852].

Ramachandran S, Hackett GI, Strange RC. Sex hormone binding globulin: a review of its interactions with testosterone and age, and its impact on mortality in men with type 2 diabetes. Sex Med Rev. 2019;7(4):669-78. doi: 10.1016/j.sxmr.2019.06.006. [PubMed: 31447413].

Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J. 2017;58(4):475-80. doi: 10.1536/ihj.17-191. [PubMed: 28717115].

Xu H, Sun L, Miao C, Jin Y, Hou Y. Type 2 diabetes mellitus is associated with increased left ventricular mass independent of coronary artery volume. Clin Radiol. 2019;74(12):972.e17-23. doi: 10.1016/j.crad.2019.07.010. [PubMed: 31420187].

Tahara N, Nitta Y, Bekki M, Tahara A, Maeda-Ogata S, Sugiyama Y, et al. Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients. J Nucl Cardiol. 2019;27(4):1352-64. doi: 10.1007/s12350-019-01842-5. [PubMed: 31407236].

Xiong SL, Lim GT, Yin SJ, Lee J, Lee JR, Hahn MJ, et al. Inhibitory effect of α-ketoglutaric acid on α-glucosidase: integrating molecular dynamics simulation and inhibition kinetics. J Biomol Struct Dyn. 2019;38(12):3496-503. doi: 10.1080/
07391102.2019.1659858
. [PubMed: 31448679].

Seah JY, Ong CN, Koh WP, Yuan JM, van Dam RM. A dietary pattern derived from reduced rank regression and fatty acid biomarkers is associated with lower risk of type 2 diabetes
and coronary artery disease in Chinese adults. J Nutr. 2019;149(11):2001-10. doi: 10.1093/jn/nxz164. [PubMed: 31386157].

Mráz M, Cinkajzlová A, Kloučková J, Lacinová Z, Kratochvílová H, Lipš M, et al. Dendritic cells in subcutaneous and epicardial adipose tissue of subjects with type 2 diabetes, obesity, and coronary artery disease. Mediators Inflamm. 2019;2019:
5481725. doi: 10.1155/2019/5481725. [PubMed: 31210749].

Tsantes AΕ, Taichert M, Kyriakou E, Katogiannis K, Lytras T, Gialeraki A, et al. The prognostic value of multiple electrode aggregometry and light transmittance aggregometry in stable cardiovascular patients with type 2 diabetes mellitus. Thromb Res. 2019;180:47-54. doi: 10.1016/j.thromres.2019.06.001. [PubMed: 31202191].

Emamalipour M, Seidi K, Jahanban-Esfahlan A, Jahanban-Esfahlan R. Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro-inflammatory cytokines. J Cell Physiol. 2019;
234(12):21758-69. doi: 10.1002/jcp.28913. [PubMed: 31187484].

Anholm C, Kumarathurai P, Jürs A, Pedersen LR, Nielsen OW, Kristiansen OP, et al. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetol Metab Syndr. 2019;11:42. doi: 10.1186/s13098-019-0438-6. [PubMed: 31164926].

Zhou JB, Zhu XR, Zhao W, Yin L, Li HB, Qi L, et al. Prediction of proliferative diabetic retinopathy to asymptomatic obstructive coronary artery disease in chinese type 2 diabetes individuals: an exploratory study. Metab Syndr Relat Disord. 2019;17(7):367-73. doi: 10.1089/met.2018.0140. [PubMed: 31145036].

Azzam SK, Osman WM, Lee S, Khalaf K, Khandoker AH, Almahmeed W, et al. Genetic associations with diabetic retinopathy and coronary artery disease in Emirati patients with type-2 diabetes mellitus. Front Endocrinol (Lausanne). 2019;10:283. doi: 10.3389/fendo.2019.00283. [PubMed: 31130920].

Senyigit A, Uzun H, Gultepe I, Konukoglu D. The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases. Bratisl Lek Listy. 2019;120(3):188-94. doi: 10.4149/BLL_2019_032. [PubMed: 31023036].

Eakin KA, Saleem M, Herrmann N, Cogo-Moreira H, Mielke MM, Oh PI, et al. Plasma sphingolipids mediate a relationship between type 2 diabetes and memory outcomes in patients with coronary artery disease undertaking exercise. J Alzheimers Dis. 2019;69(3):717-27. doi: 10.3233/JAD-181203. [PubMed: 31006687].

Kravchun PG, Kadykova OI, Molotyagin DG. Changes in pentraxin-3 level and its interaction with metabolic indices in patients with coronary artery disease and type 2 diabetes mellitus. Wiad Lek. 2019;72(2):181-5. [PubMed: 30903769].

Darwish L, Nguyen MM, Saleem M, Eakin KA, Herrmann N, Sugamori KS, et al. Lower serum osteocalcin concentrations in patients with type 2 diabetes and relationships with vascular risk factors among patients with coronary artery disease. J Diabetes Complications. 2019;33(5):390-7. doi: 10.1016/j.
jdiacomp.2019.01.003
. [PubMed: 30799280].

Ruf J, Vairo D, Paganelli F, Guieu R. Extracellular vesicles with ubiquitinated adenosine A2A receptor in plasma of patients with coronary artery disease. J Cell Mol Med. 2019;23(10):6805-11. doi: 10.1111/jcmm.14564. [PubMed: 31444994].

George AK, Majumder A, Ice H, Homme RP, Eyob W, Tyagi SC, et al. Genetics of hyperhomocysteinemia and 1-carbon metabolism: implications for retinal structure and eye functions. Can J Physiol Pharmacol. 2020;98(2):51-60. doi: 10.1139/cjpp-2019-0236. [PubMed: 31369712].

Hu Y, Xu Y, Wang G. Homocysteine levels are associated with endothelial function in newly diagnosed type 2 diabetes mellitus patients. Metab Syndr Relat Disord. 2019;17(6):323-7. doi: 10.1089/met.2019.0011. [PubMed: 31045466].